Anti-(human Tumor Necrosis Factor Receptor Superfamily Member 4 (act35 Antigen
Anti-(human Tumor Necrosis Factor Receptor Superfamily Member 4 (act35 Antigen Uses, Dosage, Side Effects, Food Interaction and all others data.
Anti-(human Tumor Necrosis Factor Receptor Superfamily Member 4 (act35 Antigen is under investigation in clinical trial NCT03029832 (A Study of MOXR0916 in Combination With Atezolizumab Versus Atezolizumab Alone in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Therapy).
| Trade Name | Anti-(human Tumor Necrosis Factor Receptor Superfamily Member 4 (act35 Antigen |
| Generic | Vonlerolizumab |
| Vonlerolizumab Other Names | Immunoglobulin g1-kappa, anti-(homo sapiens tnfrsf4(tumor necrosis factor receptor (tnfr) superfamily member 4, act35, ox40, cd134)), humanized monoclonal antibody, Immunoglobulin g1-kappa, anti-(human tumor necrosis factor receptor superfamily member 4 (act35 antigen, ox40l receptor, cd134 antigen))humanized mouse monoclonal antibody: .gamma.1 heavy chain (1-447) (humanized mouse vh (homo sapiens ighv1-46*01 (81%), Pogalizumab, Vonlerolizumab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here Anti-(human Tumor Necrosis Factor Receptor Superfamily Member 4 (act35 Antigen
